Skip to main content

Table 1 Patient characteristics

From: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Patient ID Sex Age (Years) PS (ECOG) HLA Site of Evaluable Disease Pretreatments
1 L.A. M 75 1 A2A32Cw4Cw6 spleen, soft tissue IFN
2 G.I. F 66 0 A24A11B44B18Bw4Bw6Cw5Cw7 pelvis CT+RT
3 M.G. M 73 1 A1A10B13B41Bw4Bw6 liver, lymph node CT
4 S.P. M 56 1 A9A32B38B55Bw4Bw6Cw3 lung, bone, lymph node BIOCT
5 G.C. M 51 0 A1A2B8B35Bw6Cw4Cw7 liver, lymph node IFN
6 Z.V. M 42 1 A1A19B51B14 lung BIOCT
7 G.L. M 56 2 A3A28B35B53Cw4 liver BIOCT
8 B.A. M 35 2 A2A9B7B15Bw6Cw3Cw7 lung, bone skin BIOCT
9 P.M. M 45 0 A1A9B17Bw4Bw6Cw3Cw4 lung, lymph node BIO, BIOCT
10 P.M. M 52 0 A11A31B14B60Bw6Cw3 kidney, adrenal gland BIOCT
11 R.L. F 46 1 A3A29B44Bw4 lung, liver, soft tissue CT
12 G.D. M 46 0 A3A28B21B35Cw4 lymph node NT
13 R.G. M 65 1 A10B8B38Bw4Bw6Cw7 lung, soft tissue BIOCT
14 T.A. F 61 1 A2A19B35B37Bw4Bw6Cw4 soft tissue CT+RT
15 B.A. F 59 2 A2A9B39B44Bw4Bw6Cw5 liver, soft tissue BIOCT, locoregional CT
16 C.P. F 39 0 A9A19B14B44Bw4Bw6Cw5 kidney, soft tissue Locoregional CT
17 O.M. M 56 1 A19A28B5B16Bw4Bw6 lung, soft tissue BIOCT
18 L.B. F 39 2   pelvis, lymph node BIOCT
19 M.J.L. F 37 0   lung, kidney, lymph node, soft tissue BIOCT
20 O.G. M 65 2 A23A32 adrenal gland, lymph node, soft tissue BIOCT
21 M.R. F 38 0   lymph node BIOCT
      21 Viscera: 13 BIOCT
         - 1 spleen 3 BIO
         - 5 liver 4 CT
         - 8 lung 2 Locoregional CT
         - 3 kidney 2 RT
         - 2 adrenal gland 1 NT
         - 2 pelvis  
      2 Bone  
      8 Lymph node  
      9 Soft tissue  
  1. PS (ECOG) = performance status according ECOG; CT= chemotherapy; RT= radiotherapy;
  2. BIO=Immunotherapy (Interferon, Inteleukin-2); BIOCT= chemotherapy+immunotherapy; NT= no treatment.
  3. Male/Female 13/8
  4. Median age 52 years (35–75).
  5. P.S.: 0 = 8 ; 1 = 8; 2 = 5